Horizon Discovery Limited (Horizon) announces the closing of an agreement to offer a new range of services using Horizon Discovery’s unique panel of genetically-defined human disease models called ‘isogenic’ cell lines.
Hypoxium will provide a key resource in this process by enabling pharmaceutical and academic researchers to profile their targets and drug candidates on these isogenic paired cell lines using a range of off-the-shelf and bespoke cell biology assays; from simple cell viability assays to complex mechanism of action studies, under either normal or pathological growth conditions.
Dan Cowell, CEO of Hypoxium said, “Working with Horizon Discovery is an excellent fit with our strategy of increasing our oncology focused cell biology offering with technologies that will benefit our clients’ discovery programs. By working with leaders in the field such as Horizon, we can continue to expand the tools available to researchers in cancer”.
The new offering is available now to pharmaceutical and biotech customers on standard commercial terms with a special scheduled monthly service for academic organisations that allows large numbers of individual research groups to send small numbers of compounds for affordable drug profiling.